About the Company
We do not have any company description for Allogene Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Allogene Therapeutics, Inc.
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ...
Allogene Therapeutics Inc (ALLO) showcases significant progress in clinical trials and maintains a strong cash position, ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 13, 2025 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.28. Operator: Hello, and thank you for standing ...
Allogene Therapeutics Inc. - Page 1 | BioWorld
BioWorld Content on 'Allogene Therapeutics Inc.'All gains made throughout the summer have vanished as the BioWorld Cancer Index (BCI) has hit its lowest point in 2022. Down 41.9% this year, BCI ...
ALLO | Allogene Therapeutics Inc. Profile | MarketWatch
Allogene Therapeutics Inc. 210 East Grand Avenue South San Francisco, California 94080-4811 Phone1 650 457-2700 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2025 Revenue$22K ...
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, ...
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect
Allogene Therapeutics Inc (NASDAQ:ALLO) is set to release its Q2 2025 earnings on Aug 13, 2025. The consensus estimate for Q2 2025 revenue is $0.00 million, and the earnings are expected to come in at ...
Commit To Purchase Allogene Therapeutics At $2.50, Earn 32.6% ... - Nasdaq
So unless Allogene Therapeutics Inc sees its shares decline 11% and the contract is exercised (resulting in a cost basis of $2.25 per share before broker commissions, subtracting the 25 cents from ...
Allogene Therapeutics Completes a $120 Million Private Financing
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call ...
Allogene Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Similar Companies
Loading the latest forecasts...